Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard Adjuvant Chemotherapy Plus Moxifloxacin in Operable Breast Cancer
NCT05114720Phase 3Completed
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2021
- Primary completion
- Nov 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing standard adjuvant chemotherapy plus moxifloxacin with standard adjuvant chemotherapy plus placebo (2 arms). Primary endpoint: Disease-Free Survival at 10 years. Started Nov 2021; status: completed.
02
Drugs
moxifloxacin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05114720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05114720.